Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

Sánchez-Guixé, Mònica; Muiños, Ferran; Pinheiro Santin, Morena; González-Huici, Víctor; Rodriguez-Hernandez, Carlos J; Avgustinova, Alexandra; Lavarino, Cinzia; González-Pérez, Abel; Mora, Jaume; López Bigas, Núria

doi:http://dx.doi.org/10.1158/2159-8290.CD-23-1186

Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues

Llicència

Citació

Sánchez-Guixé M, Muiños F, Pinheiro-Santin M, González-Huici V, Rodriguez-Hernandez CJ, Avgustinova A, et al. Origins of second malignancies in children and mutational footprint of chemotherapy in normal tissues. Cancer Discov. 2024 Jun 3;14(6):953-64. DOI: 10.1158/2159-8290.CD-23-1186

Resum

Pediatric cancers are rare diseases, and children without known germline predisposing conditions who develop a second malignancy during developmental ages are extremely rare. We present four such clinical cases and, through whole-genome and error-correcting ultra-deep duplex sequencing of tumor and normal samples, we explored the origin of the second malignancy in four children, uncovering different routes of development. The exposure to cytotoxic therapies was linked to the emergence of a secondary acute myeloid leukemia. A common somatic mutation acquired early during embryonic development was the driver of two solid malignancies in another child. In two cases, the two tumors developed from completely independent clones diverging during embryogenesis. Importantly, we demonstrate that platinum-based therapies contributed at least one order of magnitude more mutations per day of exposure than aging to normal tissues in these children.